Vericel Corporation (VCEL) fair value analysis
Nasdaq · Updated 2026-09-07
Vericel Corporation is a healthcare company that develops and manufactures advanced cell therapies and regenerative medicine products for patients with severe burns, chronic wounds, and other acute conditions. The company operates in the United States and internationally, serving hospitals and surgical centers through its portfolio of biologically-based therapeutic products.
Valuation status
Awaiting full valuationVCEL does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $46.05
- Sector
- Healthcare
- 12-month range
- $30.91–$46.05
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Uptrend
- 52-week position
- The top quarter of its range
What our data shows for VCEL
- Our model validated 2 trailing price-to-earnings windows for VCEL, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $30.91–$46.05.
- The 14-day relative strength index sits at a neutral 31.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for VCEL
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent VCEL news
TickrTrends' derived news-sentiment signal for VCEL is currently mixed, computed from recent coverage.
- Vericel Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VCEL) 2026-07-31 (seekingalpha.com, 2026-07-31)
TickrTrends take: Vericel Corporation's second quarter 2026 results presentation provides updated financial performance data that TickrTrends is currently processing for a complete valuation assessment. For investors focused on valuation metrics, the earnings call materials will be essential for evaluating the company's revenue trends, profitability, and cash flow generation relative to its current market valuation in the Healthcare sector. The presentation represents a key data point in determining whether VCEL's stock price appropriately reflects its operational and financial position.
What people are saying
Follow the VCEL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — VCEL's RSI indicator moved from oversold territory into neutral range this week, suggesting a shift in near-term momentum conditions. The stock remains in the Healthcare sector with a valuation verdict currently awaiting full analysis.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is VCEL stock undervalued?
VCEL does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is VCEL's TickrTrends verdict?
VCEL is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is VCEL overbought or oversold?
VCEL's 14-day RSI is in neutral territory - neither overbought nor oversold.